Effect of POD24 on the prognosis of follicular and other indolent B ...

In subsequent studies, researchers have further validated that the peak of disease progression is within 24 months of diagnosis [11].

Validation of POD24 as a robust early clinical end point of poor ...

Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of ...

Prognosis of Progressive Follicular Lymphoma within 24 Months of ...

Previous reports suggest that POD24 has less prognostic significance in patients treated with rituximab alone as front-line therapy. We aimed to ...

Progression of disease within 24 months (POD24) in follicular ...

POD24 may serve as a useful tool in identifying high-risk FL patients, however, challenges remain, as POD24 is a post-treatment endpoint, and so ...

Prognostic value of POD24 validation in follicular lymphoma patients ...

The relapse of follicular lymphoma (FL) within 24 months (POD24) of chemoimmunotherapy has been associated with poor survival. We analyzed a pooled dataset ...

Impact of early relapse within 24 months after first-line systemic ...

Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior ...

Prognosis of Progressive Follicular Lymphoma within 24 Months of ...

Previous reports suggest that POD24 has less prognostic significance in patients treated with rituximab alone as front-line therapy. We aimed to ...

Progression of Disease Within 24 Months in Follicular Lymphoma Is ...

POD24 has predicted overall survival of 26% to 50% by 5 years. ... A pooled analysis of more than 5,000 patients from 13 randomized trials ...

Survival by First-line Treatment Type and Timing of Progression

In follicular lymphoma (FL), progression of disease ≤24 months (POD24) has emerged as an important prognostic marker for overall survival (OS).

Progression of Follicular Lymphoma within 24 Months of First ...

POD24 did not predict survival in patients treated with radiation or in those initially observed, a result that may reflect their superior ...

Validation of POD24 As a Robust Early Clinical Endpoint of Poor ...

Data from the National LymphoCare Study and others identified that progression of disease within 24 months of diagnosis in patients treated with ...

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma

In pts with follicular lymphoma (FL) who received chemoimmunotherapy (CIT) as first-line treatment, progression of disease within 24 months of ...

Survival Outcomes of Patients with Follicular Lymphoma after ...

Results. Of 70 patients, 42 experienced progression of disease within 24 months (POD24), and six showed disease progression during first-line ...

Time for an individualized approach to first-line management of ...

For most patients it is a chronic, relapsing indolent disease with overall survival expectations now potentially beyond 20 years. However, in a ...

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 ...

However, lymphoma remains the primary cause of death for 10% of patients, and patients with progression of disease within 24 months (POD24) from ...

Predicting early progression in follicular lymphoma - Liu

In this cohort, 110 patients out of 588 (19%) experienced early progression within 24 months of diagnosis (POD24). The 2- and 5-year OS in the POD24 cohort were ...

Impact of transformation on the survival of patients diagnosed with ...

Background: Progression within 24 months after initiating treatment (POD24) is established as an unfavorable event predicting poor prognosis in patients with ...

Early Relapse in First-Line Follicular Lymphoma: A Review of the ...

While no single definition of early relapse has been established, progression of disease within 24 months of initial treatment (POD24) is now widely accepted ...

Association of early disease progression and very poor survival in ...

Early disease progression in patients with follicular lymphoma was associated with poor prognosis, with mortality risk higher after earlier progression.

Progression of disease within 2 years (POD24) is a clinically ...

... On the other hand, mantle cell lymphoma (MCL) typically shows a more aggressive course of disease and has the worst prognosis among B-cell ...